PMID- 27550571
OWN - NLM
STAT- MEDLINE
DCOM- 20170623
LR  - 20220410
IS  - 1952-4013 (Electronic)
IS  - 1167-1122 (Print)
IS  - 1167-1122 (Linking)
VI  - 26
IP  - 5
DP  - 2016 Oct 1
TI  - Dermatological adverse events with taxane chemotherapy.
PG  - 427-443
AB  - Taxanes (docetaxel and paclitaxel) are among the most commonly prescribed 
      anticancer drugs approved for the treatment of metastatic or locally advanced 
      breast, non-small cell lung, prostate, gastric, head and neck, and ovarian 
      cancers, as well as in the adjuvant setting for operable node-positive breast 
      cancers. Although the true incidence of dermatological adverse events (AEs) in 
      patients receiving taxanes is not known, and has never been prospectively 
      analysed, they clearly represent one of the major AEs associated with these 
      agents. With an increase in the occurrence of cutaneous AEs during treatment with 
      novel targeted and immunological therapies when used in combination with taxanes, 
      a thorough understanding of reactions attributable to this class is imperative. 
      Moreover, identification and management of dermatological AEs is critical for 
      maintaining the quality of life in cancer patients and for minimizing dose 
      modifications of their antineoplastic regimen. This analysis represents a 
      systematic review of the dermatological conditions reported with the use of these 
      drugs, complemented by experience at comprehensive cancer centres. The conditions 
      reported herein include skin, hair, and nail toxicities. Lastly, we describe the 
      dermatological data available for the new, recently FDA-and EMA- approved, 
      solvent-free nab-paclitaxel.
FAU - Sibaud, Vincent
AU  - Sibaud V
AD  - Departments of Oncodermatology and Clinical Research, Institut Claudius Regaud, 
      Institut Universitaire du Cancer, Toulouse Oncopole, France.
FAU - Leboeuf, Nicole R
AU  - Leboeuf NR
AD  - Department of Dermatology, Dana-Farber/ Brigham and Women's Cancer Center/ 
      Harvard Medical School, Boston, MA, USA.
FAU - Roche, Henri
AU  - Roche H
AD  - Department of Oncology, Institut Claudius Regaud, Institut Universitaire du 
      Cancer, Toulouse Oncopole, France.
FAU - Belum, Viswanath R
AU  - Belum VR
AD  - Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
FAU - Gladieff, Laurence
AU  - Gladieff L
AD  - Department of Oncology, Institut Claudius Regaud, Institut Universitaire du 
      Cancer, Toulouse Oncopole, France.
FAU - Deslandres, Marion
AU  - Deslandres M
AD  - Department of Oncology, Institut Claudius Regaud, Institut Universitaire du 
      Cancer, Toulouse Oncopole, France.
FAU - Montastruc, Marion
AU  - Montastruc M
AD  - Department of Oncology, Institut Claudius Regaud, Institut Universitaire du 
      Cancer, Toulouse Oncopole, France.
FAU - Eche, Audrey
AU  - Eche A
AD  - Department of Oncology, Institut Claudius Regaud, Institut Universitaire du 
      Cancer, Toulouse Oncopole, France.
FAU - Vigarios, Emmanuelle
AU  - Vigarios E
AD  - Department of Oral Medicine, Institut Claudius Regaud, Institut Universitaire du 
      Cancer, Toulouse Oncopole, France.
FAU - Dalenc, Florence
AU  - Dalenc F
AD  - Department of Oncology, Institut Claudius Regaud, Institut Universitaire du 
      Cancer, Toulouse Oncopole, France.
FAU - Lacouture, Mario E
AU  - Lacouture ME
AD  - Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
PT  - Systematic Review
PL  - France
TA  - Eur J Dermatol
JT  - European journal of dermatology : EJD
JID - 9206420
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Taxoids)
RN  - 15H5577CQD (Docetaxel)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Alopecia/chemically induced
MH  - Antineoplastic Agents/*adverse effects
MH  - Docetaxel
MH  - Drug Eruptions/*etiology
MH  - Edema/chemically induced
MH  - Humans
MH  - Lupus Erythematosus, Cutaneous/chemically induced
MH  - Nail Diseases/chemically induced
MH  - Paclitaxel/*adverse effects
MH  - Pigmentation Disorders/chemically induced
MH  - Radiodermatitis/chemically induced
MH  - Taxoids/*adverse effects
PMC - PMC5526115
MID - NIHMS878998
OTO - NOTNLM
OT  - docetaxel
OT  - hair
OT  - nab-paclitaxel
OT  - nail
OT  - paclitaxel
OT  - skin
OT  - taxanes
OT  - toxicity
COIS- Conflict of interest: NRL, HR, FD, VRB, AE, LG, MM, MD and EV have no conflicts 
      of interest to declare.
EDAT- 2016/10/30 06:00
MHDA- 2017/06/24 06:00
PMCR- 2017/10/01
CRDT- 2016/08/24 06:00
PHST- 2016/10/30 06:00 [pubmed]
PHST- 2017/06/24 06:00 [medline]
PHST- 2016/08/24 06:00 [entrez]
PHST- 2017/10/01 00:00 [pmc-release]
AID - ejd.2016.2833 [pii]
AID - 10.1684/ejd.2016.2833 [doi]
PST - ppublish
SO  - Eur J Dermatol. 2016 Oct 1;26(5):427-443. doi: 10.1684/ejd.2016.2833.